Skip to main content
Premium Trial:

Request an Annual Quote

Osmetech and Epidauros to Co-Develop Companion Dx Products; HIV, Cancer to Be a Focus

NEW YORK (GenomeWeb News) — Osmetech and Epidauros plan to jointly develop companion diagnostics for pharmaceuticals and pharmacogenomic biomarkers, the companies said today.

Under the terms of the agreement, Osmetech will use Epidauros’ biomarkers to develop and market assays for its eSensor array systems, the companies said.

Osmetech CEO James White said the agreement gives the company “access to a very strong pipeline” of companion diagnostics for biomarkers and pharmaceutical development. He said the company will use these in its efforts to expand its market position by “linking the drug to the diagnostic.”

Epidauros CEO Michael Lutz said the deal will spur advances not only in the company’s biomarker pipeline, “but also any personalized medicine-related marker our pharma partners may want to develop into molecular diagnostic tests, in particular in the fields of HIV and oncology.”

This is not the first deal between the two companies. In October 2006 Osmetech said it will use Epidauros’ CYP450 2D6 biomarker patent to expand into pharmacogenomics testing.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.